Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCLA-129 in Advanced NSCLC and Other Solid Tumors
NCT04930432Phase 2Recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pamvatamig in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Betta Pharmaceuticals. Started Sep 2021; status: recruiting.
02
Drugs
pamvatamig
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04930432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930432.